Neurodegeneration News and Research

RSS

Neurodegeneration is the umbrella term for the progressive loss of structure or function of neurons, including death of neurons.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

9 Mar 2011

Neurodegenerative Disease Management – meeting the challenge of neurodegenerative diseases

Future Medicine Ltd has today announced the launch of Neurodegenerative Disease Management – a new bimonthly title addressing all the latest trends in the field, from R&D through to clinical application and management, presenting research, findings, analysis and commentaries from experts around the world.

3 Mar 2011

Viruses that are natural part of human genome may retrovirus culprit

A retrovirus that inserted itself into the human genome thousands of years ago may be responsible for some cases of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), also known as Lou Gherig’s disease. The finding, made by Johns Hopkins scientists, may eventually give researchers a new way to attack this universally fatal condition.

2 Mar 2011

Mathematical model predicts lifespan of stem cells

When patients receive a bone marrow transplant, they are getting a new population of hematopoietic stem cells. Fresh stem cells are needed when a patient is low on red blood cells, as in anemia, or white blood cells, which can be caused by cancer or even cancer treatments such as irradiation or chemotherapy. The problem is that a bone marrow transplant might not succeed because the transplanted stem cells don't live long enough or because they proliferate too well, leading to leukemia.

2 Mar 2011

Diabetes technology granted patent in Australia

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) a global company pioneering the development of a cell implant therapy to treat diabetes and neurodegenerative diseases, has been granted a patent by the Australian Patent Office for IMMUPEL(tm), LCT's industry-leading technology for encapsulating living cells prior to transplantation.

23 Feb 2011

Deactivation of CRTC1 protein increases lifespan

Substantial evidence suggests that lifespan is increased if an organism restricts its daily calorie intake, a spartan regime that some say works by just making life seem longer. A team of scientists from the Salk Institute of Biological Studies has discovered a molecular switch flipped by hunger that could not only make longevity more appetizing but identify drug targets for patients with aging-related diseases such as type II diabetes or cancer.

17 Feb 2011

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

Amicus Therapeutics today announced that additional positive data from the ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease will be presented at the Lysosomal Disease Network WORLD Symposium in Las Vegas, Nevada, February 16-18th, 2011.

17 Feb 2011

Research: MEF2D protein in mitochondria appears to contribute early steps in Parkinson's disease

For the last several years, neurologists have been probing a connection between Parkinson's disease and problems with mitochondria, the miniature power plants of the cell.

15 Feb 2011

PsychoGenics establishes alliance with KineMed to provide specialized neurogenesis services

PsychoGenics today announced the establishment of an alliance with KineMed, to provide specialized neurogenesis services to complement PsychoGenics' in vivo testing capabilities.

15 Feb 2011

Novel technology to diagnose Alzheimer's disease before symptoms appear

UT Southwestern Medical Center scientists have helped develop a novel technology to diagnose Alzheimer's disease from blood samples long before symptoms appear.

14 Feb 2011

CX3CL1 signaling chemical can offer better understanding of Parkinson's disease

Targeting the neuroinflammatory causes of Parkinson's disease with a naturally present brain chemical signal could offer a better understanding of the clinical mechanisms of the disease and open a future therapeutic window, reports a team of researchers from the University of South Florida Department Neurosurgery and Brain Repair and the James A. Haley Veterans' Administration Hospital, Tampa.

14 Feb 2011

Scientists produce SR-3306 compound to protect brain cells from Parkinson's disease

Scientists from the Florida campus of The Scripps Research Institute have produced the first known compound to show significant effectiveness in protecting brain cells directly affected by Parkinson's disease, a progressive and fatal neurodegenerative disorder.

13 Feb 2011

Research provides new clues to understand link between deficits of AGPO-3, depression

The link between deficits of omega-3 poly-unsaturated fatty acids and the onset of depressive disorders is not new in the medical field. However, what has not been known until now is the brain mechanism by which diet can condition mental health to a certain extent.

5 Feb 2011

Salk Institute receives $2.3 million CIRM grant for translational research on Parkinson's disease

The Salk Institute has been awarded a $2.3 million grant by the California Institute for Regenerative Medicine for translational research focusing on developing a novel stem cell based therapy for Parkinson's disease.

4 Feb 2011

Generation of iPSCs can be enhanced by modulating miRNA action

Stem cells are ideal tools to understand disease and develop new treatments; however, they can be difficult to obtain in necessary quantities. In particular, generating induced pluripotent stem (iPS) cells can be an arduous task because reprogramming differentiated adult skin cells into iPS cells requires many steps and the efficiency is very low - researchers might end up with only a few iPS cells even if they started with a million skin cells.

3 Feb 2011

Defective nucleoli linked to Parkinson's disease

"Nucleolus", or small nucleus, is the term coined by early biologists for the tiny structure within the nucleus which they saw under the microscope. In this structure within the nucleus, RNA molecules and proteins are assembled to form ribosomes, the true protein factories of cells.

2 Feb 2011

Neurodegeneration News and Research

Further Reading

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Neurodegenerative Disease Management – meeting the challenge of neurodegenerative diseases

Viruses that are natural part of human genome may retrovirus culprit

Mathematical model predicts lifespan of stem cells

Diabetes technology granted patent in Australia

Deactivation of CRTC1 protein increases lifespan

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

Research: MEF2D protein in mitochondria appears to contribute early steps in Parkinson's disease

PsychoGenics establishes alliance with KineMed to provide specialized neurogenesis services

Novel technology to diagnose Alzheimer's disease before symptoms appear

CX3CL1 signaling chemical can offer better understanding of Parkinson's disease

Scientists produce SR-3306 compound to protect brain cells from Parkinson's disease

Research provides new clues to understand link between deficits of AGPO-3, depression

Salk Institute receives $2.3 million CIRM grant for translational research on Parkinson's disease

Generation of iPSCs can be enhanced by modulating miRNA action

Defective nucleoli linked to Parkinson's disease

KineMed's fibrosis research program featured in Nature Medicine

Study may help develop novel ways to combat lipotoxic cardiomyopathy, related heart disease

MicroRNA-29 molecule makes brain cells resistant to programmed cell death

OMJPI, Sanford-Burnham enter agreement to discover compounds for Alzheimer's disease, psychiatric disorders

Aneuro: A Year of Neuroscience in Review eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News